Abivax (ABVX) Gains from Investment Securities (2024 - 2025)

Abivax (ABVX) recorded quarterly Gains from Investment Securities of $74.0 million in Q3 2025, up 4123.15% quarter-over-quarter from $1.8 million in Q2 2025, and up 25602.0% on a YoY basis from N/an in Q3 2024.

Abivax (ABVX) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Abivax's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $74.0 million for Q3 2025.

  • In Q3 2025, Gains from Investment Securities rose 25602.0% year-over-year to $74.0 million; the TTM figure through Mar 2026 stood at $75.1 million (up 2335.35% YoY), while the FY2025 annual figure was $72.6 million, up 4695.01% from the prior year.
  • Gains from Investment Securities was $74.0 million for Q3 2025 at Abivax, up from $1.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $74.0 million in Q3 2025 to a low of -$417162.9 in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn

Historic Data

Download Data
DateValue
Sep 30, 2025 73.95 Mn
Sep 30, 2025 73.95 Mn
Jun 30, 2025 1.75 Mn
Jun 30, 2025 1.75 Mn
Mar 31, 2025 1.14 Mn
Mar 31, 2025 1.14 Mn
Dec 31, 2024 -293,863.74
Dec 31, 2024 -293,863.74
Sep 30, 2024 287,733.51
Sep 30, 2024 287,733.51
Jun 30, 2024 1.95 Mn
Jun 30, 2024 1.95 Mn
Mar 31, 2024 -417,162.92
Mar 31, 2024 -417,162.92